Durect Corp (DRRX)
1.13
+0.11
(+10.78%)
USD |
NASDAQ |
May 09, 16:00
1.11
-0.02
(-1.77%)
After-Hours: 20:00
Durect Research and Development Expense (Quarterly): 5.613M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.613M |
| September 30, 2023 | 7.199M |
| June 30, 2023 | 7.946M |
| March 31, 2023 | 8.593M |
| December 31, 2022 | 9.953M |
| September 30, 2022 | 9.881M |
| June 30, 2022 | 8.817M |
| March 31, 2022 | 8.211M |
| December 31, 2021 | 8.415M |
| September 30, 2021 | 8.023M |
| June 30, 2021 | 7.433M |
| March 31, 2021 | 7.975M |
| December 31, 2020 | 6.685M |
| September 30, 2020 | 6.87M |
| June 30, 2020 | 6.567M |
| March 31, 2020 | 7.587M |
| December 31, 2019 | 8.885M |
| September 30, 2019 | 7.906M |
| June 30, 2019 | 6.598M |
| March 31, 2019 | 6.251M |
| December 31, 2018 | 5.399M |
| September 30, 2018 | 6.542M |
| June 30, 2018 | 6.12M |
| March 31, 2018 | 6.952M |
| December 31, 2017 | 6.604M |
| Date | Value |
|---|---|
| September 30, 2017 | 8.378M |
| June 30, 2017 | 9.079M |
| March 31, 2017 | 7.548M |
| December 31, 2016 | 7.992M |
| September 30, 2016 | 6.805M |
| June 30, 2016 | 7.852M |
| March 31, 2016 | 6.625M |
| December 31, 2015 | 6.658M |
| September 30, 2015 | 6.654M |
| June 30, 2015 | 5.638M |
| March 31, 2015 | 5.367M |
| December 31, 2014 | 5.409M |
| September 30, 2014 | 5.463M |
| June 30, 2014 | 6.088M |
| March 31, 2014 | 5.469M |
| December 31, 2013 | 4.85M |
| September 30, 2013 | 4.473M |
| June 30, 2013 | 4.833M |
| March 31, 2013 | 4.789M |
| December 31, 2012 | 4.904M |
| September 30, 2012 | 4.745M |
| June 30, 2012 | 4.982M |
| March 31, 2012 | 5.634M |
| December 31, 2011 | 7.013M |
| September 30, 2011 | 8.452M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.613M
Minimum
Dec 2023
9.953M
Maximum
Dec 2022
7.850M
Average
7.946M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |
| Oragenics Inc | 11.04M |